Compare AbbVie Inc (ABBV) vs SoFi Technologies Inc (SOFI) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

SOFI stock trades at $17.75, down 2.69% on the day, with a bullish technical signal and strong support at $17. The company reported revenue growth to $3.61B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion into small business loans and AI-driven products like Coach and Composer, aiming to deepen member engagement.

Outlook remains positive with a consensus price target of $21.22, offering 20% upside potential. Key risks include negative operating cash flow and high valuation multiples. Growth catalysts are centered on loan originations and ecosystem expansion, but investors should monitor execution and interest rate sensitivity.